{"protocolSection":{"identificationModule":{"nctId":"NCT00409188","orgStudyIdInfo":{"id":"EMR 63325-001"},"organization":{"fullName":"EMD Serono","class":"INDUSTRY"},"briefTitle":"Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","officialTitle":"A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.","acronym":"START"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-01"},"primaryCompletionDateStruct":{"date":"2012-04","type":"ACTUAL"},"completionDateStruct":{"date":"2015-04","type":"ACTUAL"},"studyFirstSubmitDate":"2006-12-07","studyFirstSubmitQcDate":"2006-12-07","studyFirstPostDateStruct":{"date":"2006-12-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-07-23","resultsFirstSubmitQcDate":"2015-10-19","resultsFirstPostDateStruct":{"date":"2015-11-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-19","lastUpdatePostDateStruct":{"date":"2015-11-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"EMD Serono","class":"INDUSTRY"},"collaborators":[{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.\n\nA local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.","detailedDescription":"Ancillary Trial: An exploratory investigation of immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.\n\nThe ancillary study is a sub-study within START. This is an exploratory investigation of the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination. The main objective is to evaluate whether administration of single-shot, low-dose cyclophosphamide followed by tecemotide (L-BLP25) vaccinations induces specific immune response in peripheral blood to BLP25 (the mucinous glycoprotein 1 \\[MUC1\\] antigen) as well as a modulation of cellular and soluble components of the immune response in subjects with unresectable stage III NSCLC.\n\nTwenty-five of the European START sites will participate in the ancillary study.\n\nSample size: up to 60 to 80 subjects\n\nAll inclusion criteria specified in the START clinical trial protocol except for hemoglobin \\>= 100 gram/Liter (g/L)\n\nAll exclusion criteria are the same as specified in the START clinical trial protocol\n\nSchedule of events: Blood samples will be taken at baseline, visit week 4, 8 13 and 25 (80 milliliter (mL) whole blood each)"},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Non-Small Cell Lung Carcinoma;","stage III;","unresectable;","vaccine; Tecemotide; L-BLP25;","Cyclophosphamide;","placebo controlled;","randomized;","double blind;","immunotherapy;"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1513,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tecemotide (L-BLP25)","type":"EXPERIMENTAL","interventionNames":["Biological: Tecemotide (L-BLP25)","Drug: Single low dose cyclophosphamide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Tecemotide (L-BLP25)","description":"After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.","armGroupLabels":["Tecemotide (L-BLP25)"]},{"type":"DRUG","name":"Single low dose cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.","armGroupLabels":["Tecemotide (L-BLP25)"]},{"type":"DRUG","name":"Placebo","description":"A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival","description":"Overall survival time was defined as the time from randomization to death. Participants without events were censored at the last date they were known to be alive or the clinical cut-off date, whatever was earlier.","timeFrame":"Up to 66 months"}],"secondaryOutcomes":[{"measure":"Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)","description":"Time to symptom progression (TTSP) was measured by LCSS. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where higher score indicates worst outcome). Worsening was defined as a 10% increase in the scale breadth from the baseline score. TTSP is defined as the time from randomization to worsening in ASBI. Participants without event are censored at the date of the last LCSS assessment.","timeFrame":"Up to 66 months"},{"measure":"Time To Progression (TTP)","description":"Time from randomization to disease progression. Disease progression was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 \\[RECIST v1.0\\]) as at least a 20% increase in the sum of the longest diameter of target lesions from nadir, or the appearance of one or more new lesions.","timeFrame":"Up to 66 months"},{"measure":"One-, Two- and Three-year Survival Rate","description":"The percentages of participants who were alive at 1, 2, and 3 years were calculated as a cumulative percentage by Kaplan-Meier survival analysis approach.","timeFrame":"Years 1, 2, and 3"},{"measure":"Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions","description":"Treatment -emergent adverse events were defined as those with onset or worsening occurring at or after the first dosing day of study medication and up to 42 days after the last administration of any study drug or the clinical cut-off date. Injection site reactions were reported as assessed by the Investigator.","timeFrame":"From first dose up to 42 days after the last dose of the trial treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented unresectable stage III non-small cell lung cancer (NSCLC)\n* Documented stable disease or objective response, according to Response Evaluation Criteria in Solid Tumors (RECIST), after primary chemoradiotherapy (either sequential or concomitant) for unresectable stage III disease, within 4 weeks (28 days) prior to randomization\n* Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of \\>=50 Gray (Gy). Subjects must have completed the primary thoracic chemo-radiotherapy at least four weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible\n* Geographically accessible for ongoing follow-up, and committed to comply with the designated visits\n* An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* A platelet count \\> 140 x 10\\^9/Liter; white blood cells (WBC) \\> 2.5 x 10\\^9/Liter and hemoglobin \\> 90 gram per liter (g/L)\n\nExclusion Criteria:\n\nPre-Therapies:\n\n* Undergone lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy\n* Receipt of immunotherapy (e.g. interferons, tumor necrosis factor \\[TNF\\], interleukins, or biological response modifiers \\[granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}\\], monoclonal antibodies) within 4 weeks (28 days) prior to randomization\n* Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to randomization\n\nDisease Status:\n\n* Metastatic disease\n* Malignant pleural effusion at initial diagnosis and/or at study entry\n* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years\n* Autoimmune disease\n* A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies\n* Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed)\n* Known Hepatitis B and/or C\n\nPhysiological Functions:\n\n* Clinically significant hepatic dysfunction\n* Clinically significant renal dysfunction\n* Clinically significant cardiac disease\n* Splenectomy\n* Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response\n\nStandard Safety:\n\n* Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator\n* Known drug abuse/alcohol abuse\n* Legal incapacity or limited legal capacity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Responsible","affiliation":"EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Saint Edward Mercy Medical Center","city":"Fort Smith","state":"Arkansas","zip":"72901","country":"United States","geoPoint":{"lat":35.38592,"lon":-94.39855}},{"facility":"Pacific Cancer Medical Center","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Glendale Adventist Medical Center","city":"Glendale","state":"California","zip":"91206","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"Norris Cancer Hospital","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Clinical Trials and Research Associates, Inc.","city":"Montebello","state":"California","zip":"90640","country":"United States","geoPoint":{"lat":34.00946,"lon":-118.10535}},{"facility":"Desert Hematology Oncology Medical Group, Inc","city":"Rancho Mirage","state":"California","country":"United States","geoPoint":{"lat":33.73974,"lon":-116.41279}},{"facility":"Stockton Hematology Oncology Medical Group, Inc.","city":"Stockton","state":"California","zip":"95204","country":"United States","geoPoint":{"lat":37.9577,"lon":-121.29078}},{"facility":"University of Colorado Cancer Center","city":"Denver","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Pasco Hernando Oncology Associates P.A","city":"Brooksville","state":"Florida","zip":"34613","country":"United States","geoPoint":{"lat":28.55554,"lon":-82.38991}},{"facility":"University of Miami, Sylvester Comprehensive Cancer Center","city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Pasco Hernando Oncology Associates, PA","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"Florida Hospital Memorial System","city":"Ormond Beach","state":"Florida","zip":"32174","country":"United States","geoPoint":{"lat":29.28581,"lon":-81.05589}},{"facility":"Southern Illinois Hematology/Oncology","city":"Centralia","state":"Illinois","zip":"62801","country":"United States","geoPoint":{"lat":38.52505,"lon":-89.1334}},{"facility":"Rush University Medical Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Joliet Oncology-Hematology Associates, Ltd.","city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"Kentucky Cancer Center","city":"Hazard","state":"Kentucky","zip":"41701","country":"United States","geoPoint":{"lat":37.24954,"lon":-83.19323}},{"facility":"Leonard J. Chabert Medical Center","city":"Houma","state":"Louisiana","country":"United States","geoPoint":{"lat":29.59577,"lon":-90.71953}},{"facility":"Hematology and Oncology Specialists, LLC","city":"Metarie","state":"Louisiana","zip":"70006","country":"United States"},{"facility":"Sinai Hospital of Baltimore","city":"Baltimore","state":"Maryland","zip":"21215","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"University of Maryland, Marlene and Steward Greenbaum Cancer Center","city":"Baltimore","state":"Maryland","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Lahey Clinic","city":"Burlington","state":"Massachusetts","country":"United States","geoPoint":{"lat":42.50482,"lon":-71.19561}},{"facility":"Oncology Care Associates","city":"Saint Joseph","state":"Michigan","zip":"49085","country":"United States","geoPoint":{"lat":42.10976,"lon":-86.48002}},{"facility":"University of Minnesota Physicians, Masonic Cancer Center","city":"Minneapolis","state":"Minnesota","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Saint Louis University Cance Center","city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Deaconess Billings Clinic","city":"Billings","state":"Montana","zip":"59101","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Big Sky Oncology, Sletten Cancer Institute","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Nebraska Cancer Care, LLC","city":"Hastings","state":"Nebraska","zip":"68901","country":"United States","geoPoint":{"lat":40.58612,"lon":-98.38839}},{"facility":"Southeast Nebraska Cancer Center","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"St. Vincents Comprehensive Cancer Center","city":"New York","state":"New York","zip":"10011","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Hematology Oncology Associates of Rockland","city":"Nyack","state":"New York","zip":"10960","country":"United States","geoPoint":{"lat":41.09065,"lon":-73.91791}},{"facility":"Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Carolinas Hematology-Oncology","city":"Charlotte","state":"North Carolina","zip":"28203","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Hanover Medical Specialts PA","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Gabrail Cancer Center","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"University Hospitals of Cleveland","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Signal Point Clinical Research Center, LLC","city":"Middletown","state":"Ohio","zip":"45042","country":"United States","geoPoint":{"lat":39.51506,"lon":-84.39828}},{"facility":"Southwestern Regional Medical Center","city":"Tulsa","state":"Oklahoma","zip":"74133","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Southwestern Regional Medical Center","city":"Tulsa","state":"Oklahoma","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Providence Portland Medical Center","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Univ. of Pennsylvania Abramson Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"The Jones Clinic, PC","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Center for Oncology Research","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"John Peter Smith Center for Cancer Care","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"The Center for Cancer and Blood Disorders","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Cancer Therapy & Research Center, Institute for Drug Development","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Fairfax-Northern Virginia Hematology Oncology, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Wheeling Hospital","city":"Wheeling","state":"West Virginia","zip":"26003","country":"United States","geoPoint":{"lat":40.06396,"lon":-80.72091}},{"facility":"Hospital Italiano Regional del Sur","city":"Bahía Blanca","state":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-38.7176,"lon":-62.26545}},{"facility":"Paliar","city":"Capital, Buenos Aires","state":"Buenos Aires","country":"Argentina"},{"facility":"Corporacion Medica General San Martin","city":"San Martín","state":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-35.02575,"lon":-57.75317}},{"facility":"Centro Oncologico de Roario","city":"Rosario","state":"Santa Fe Province","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Centro de Educacion Medica e Investigaciones Clinicas \"Norberto Quirno\" (CEMIC)","city":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Instituto Especializado Alexander Fleming","city":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Sociedad Intaliana de Beneficencia en Buenos Aires, Hospital Italiano","city":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Clinica Universitaria Reina Fabiola","city":"Córdoba","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Research Site","city":"Tandil","country":"Argentina","geoPoint":{"lat":-37.3287,"lon":-59.1369}},{"facility":"Research Site","city":"Nedlands","state":"Western Australia","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Research Site","city":"Bankstown, NSW","country":"Australia","geoPoint":{"lat":-33.91667,"lon":151.03333}},{"facility":"Research Site","city":"Camperdown","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Research Site","city":"Heidelberg","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Research Site","city":"Kingswood","country":"Australia","geoPoint":{"lat":-33.75614,"lon":150.72346}},{"facility":"Research Site","city":"Saint Leonards","country":"Australia","geoPoint":{"lat":-38.17051,"lon":144.71803}},{"facility":"Research Site","city":"Woolloongabba","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Research Site","city":"Graz","state":"Styria","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Research Site","city":"Linz","state":"Upper Austria","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Research Site","city":"Inssbruck","country":"Austria"},{"facility":"Research Site","city":"Salzburg","country":"Austria","geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"Research Site","city":"Vienna","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Wein, Venna","country":"Austria"},{"facility":"Research Site","city":"Wels","country":"Austria","geoPoint":{"lat":48.16667,"lon":14.03333}},{"facility":"Research Site","city":"Brasschaat","country":"Belgium","geoPoint":{"lat":51.2912,"lon":4.49182}},{"facility":"Research Site","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Research Site","city":"Haine-Saint-Paul","country":"Belgium","geoPoint":{"lat":50.45544,"lon":4.1885}},{"facility":"Research Site","city":"Leuven","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Research Site","city":"Liège","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Research Site","city":"Mechelen","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"Hospital das Clinicas da Faculdade de Medinina de Univeridade","city":"São Paulo","state":"De Ao Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Nugieo de Oncologia da Bahia","city":"Salvador","state":"Estado de Bahia","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Hospital LifeCenter","city":"Belo Horizonte","state":"Minas Gerais","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Hospital Nossa Senhora da Conceicao, Centro de Pesquisas Medicas e Ensaios Clinicos","city":"Porto Alegre","state":"Rio Grande Do Sol","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Associacao Hospital de Caridade Ijui","city":"Ijuí","state":"Rio Grande do Sul","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Hospital de Clinicas de Porto Alegre, Dept. de Endocrinologia","city":"Porto Alegre","state":"Rio Grande do Sul","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Sao Lucas-Pucrs","city":"Porto Alegre","state":"Rio Grande do Sul","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Porto Algre","state":"Rio Grande do Sul","country":"Brazil"},{"facility":"Centro de Oncologia de Campinas - OCC","city":"Campinas","state":"São Paulo","country":"Brazil","geoPoint":{"lat":-22.90556,"lon":-47.06083}},{"facility":"Fundacao Hospital Amaral Carvalho","city":"Jaú","state":"São Paulo","country":"Brazil","geoPoint":{"lat":-22.29639,"lon":-48.55778}},{"facility":"Instituto do Cancer Arnaldo Vieira de Caralho-Onco-pneumonia","city":"São Paulo","state":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Santa Casa de Misericordia De Sao Paulo","city":"São Paulo","state":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Instituto de Oncologia de Sorocaba","city":"Sorocaba","state":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.50167,"lon":-47.45806}},{"facility":"Research Site","city":"Ondina-Salvdor","country":"Brazil"},{"facility":"Instituto Nacional do Cancer - INCA","city":"Rio de Janeriro","country":"Brazil"},{"facility":"Tom Baker Cancer Center","city":"Calgary","state":"Alberta","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Cross Cancer Institue","city":"Edmonton","state":"Alberta","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Frazer Valley Cancer Center","city":"Surrey","state":"British Columbia","country":"Canada","geoPoint":{"lat":49.10635,"lon":-122.82509}},{"facility":"British Columbia Cancer Agency","city":"Vancouver","state":"British Columbia","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Vancouver Island Cancer Center","city":"Victoria","state":"British Columbia","country":"Canada","geoPoint":{"lat":48.4359,"lon":-123.35155}},{"facility":"Cancer Care Manitoba","city":"Winnipeg","state":"Manitoba","country":"Canada","geoPoint":{"lat":49.8844,"lon":-97.14704}},{"facility":"Capital District Health Authority","city":"Halifax","state":"Nova Scotia","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Cape Breton Districk Health Authority Cancer Care","city":"Sydney","state":"Nova Scotia","country":"Canada","geoPoint":{"lat":46.1351,"lon":-60.1831}},{"facility":"Juravinski Cancer Center","city":"Hamilton","state":"Ontario","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Niagara Health System","city":"St. Catharines","state":"Ontario","country":"Canada","geoPoint":{"lat":43.17126,"lon":-79.24267}},{"facility":"Thunder Bay Regional Health Science Center Northwestern Ontario Regional Center","city":"Thunder Bay","state":"Ontario","country":"Canada","geoPoint":{"lat":48.38202,"lon":-89.25018}},{"facility":"Mount Sinai Hospital","city":"Toronto","state":"Ontario","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Princess Margaret Hospital","city":"Toronto","state":"Ontario","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Windsor Regional Cancer Center","city":"Windsor","state":"Ontario","country":"Canada","geoPoint":{"lat":42.30008,"lon":-83.01654}},{"facility":"Hopital Notre Dame","city":"Montreal","state":"Quebec","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Jewish General Hospital","city":"Montreal","state":"Quebec","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Hopital Laval","city":"Sainte-Foy","state":"Quebec","country":"Canada","geoPoint":{"lat":46.78139,"lon":-71.29217}},{"facility":"Research Site","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Guangzhou","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Shanghai","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Hradec Králové","country":"Czechia","geoPoint":{"lat":50.20923,"lon":15.83277}},{"facility":"Research Site","city":"Ostrava-Poruba","country":"Czechia"},{"facility":"Research Site","city":"Prague","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Ústí nad Labem","country":"Czechia","geoPoint":{"lat":50.6607,"lon":14.03227}},{"facility":"Research Site","city":"Herlev","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Research Site","city":"Odense C","country":"Denmark","geoPoint":{"lat":55.40841,"lon":10.39538}},{"facility":"Research Site","city":"Pierre-Bénite","state":"Auvergne-Rhône-Alpes","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Research Site","city":"Besançon","state":"Franche-Comte","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Research Site","city":"Beuvry","country":"France","geoPoint":{"lat":50.51674,"lon":2.68541}},{"facility":"Research Site","city":"Brest","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Research Site","city":"Caen","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Research Site","city":"Chauny","country":"France","geoPoint":{"lat":49.61514,"lon":3.21857}},{"facility":"Research Site","city":"Marseille","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Research Site","city":"Nancy","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}},{"facility":"Research Site","city":"Nantes-Saint Herblain","country":"France"},{"facility":"Research Site","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Perpignan","country":"France","geoPoint":{"lat":42.69764,"lon":2.89541}},{"facility":"Research Site","city":"Poitiers","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Research Site","city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Research Site","city":"Essen","state":"North Rhine-Westphalia","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Research Site","city":"Hemer","state":"North Rhine-Westphalia","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Research Site","city":"Mainz","state":"Rhineland-Palatinate","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Research Site","city":"Homburg","state":"Saarland","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Research Site","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Cologne","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Research Site","city":"Coswig","country":"Germany","geoPoint":{"lat":51.13204,"lon":13.58312}},{"facility":"Research Site","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Research Site","city":"Frankfurt am Main","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Research Site","city":"Freiburg im Breisgau","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Research Site","city":"Gauting","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Research Site","city":"Großhansdorf","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Research Site","city":"Hamburg","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Reseach Site","city":"Heidelberg","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Kassel","country":"Germany","geoPoint":{"lat":51.31667,"lon":9.5}},{"facility":"Research Site","city":"Kiel","country":"Germany","geoPoint":{"lat":54.32133,"lon":10.13489}},{"facility":"Research Site","city":"Leipzig","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Research Site","city":"Magdeburg","country":"Germany","geoPoint":{"lat":52.13129,"lon":11.63189}},{"facility":"Research Site","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Research Site","city":"Minden","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"facility":"Research Site","city":"Mutzschen","country":"Germany","geoPoint":{"lat":51.26159,"lon":12.89125}},{"facility":"Research Site","city":"München","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Research Site","city":"Oldenburg","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Research Site","city":"Rostock","country":"Germany","geoPoint":{"lat":54.0887,"lon":12.14049}},{"facility":"Research Site","city":"Marousi","state":"Athens","country":"Greece","geoPoint":{"lat":38.05,"lon":23.8}},{"facility":"Research Site","city":"Athens","state":"Attica","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Thessaloniki","state":"Nea Efkarpia","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Research Site","city":"Athens","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Chidari, Athens","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Heraklion","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"Research Site","city":"Shatin","state":"New Territories","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Research Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Research Site","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Mátraháza","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Research Site","city":"Nyíregyháza","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Research Site","city":"Tatabayana","country":"Hungary"},{"facility":"Research Site","city":"Chennai","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Research Site","city":"Hyderabad","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Research Site","city":"Mumbai","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Research Site","city":"New Delhi","country":"India","geoPoint":{"lat":28.62137,"lon":77.2148}},{"facility":"Research Site","city":"Vellore","country":"India","geoPoint":{"lat":12.9184,"lon":79.13255}},{"facility":"Research Site","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Research Site","city":"Tel Litwinsky","state":"Tel Avir","country":"Israel","geoPoint":{"lat":32.05096,"lon":34.84588}},{"facility":"Research Site","city":"Beersheba","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Research Site","city":"Haifa","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Research Site","city":"Jerusalem","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Research Site","city":"Kfar Saba","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Research Site","city":"Petah Tikva","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Research Site","city":"Tel Aviv","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Research Site","city":"Ẕerifin","country":"Israel","geoPoint":{"lat":31.95731,"lon":34.84852}},{"facility":"Research Site","city":"Genova","state":"Genova","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Research Site","city":"Palermo","state":"Palermo","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Research Site","city":"Candiolo","state":"Torino","country":"Italy","geoPoint":{"lat":44.95858,"lon":7.59812}},{"facility":"Research Site","city":"Avelino","country":"Italy"},{"facility":"Research Site","city":"Bologna","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Research Site","city":"Carpi","country":"Italy","geoPoint":{"lat":44.78237,"lon":10.8777}},{"facility":"Research Site","city":"Chieti","country":"Italy","geoPoint":{"lat":42.34827,"lon":14.16494}},{"facility":"Research Site","city":"Forlì","country":"Italy","geoPoint":{"lat":44.22177,"lon":12.04144}},{"facility":"Research Site","city":"Meldola","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Research Site","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Napoli","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Research Site","city":"Orbassano-Torino","country":"Italy"},{"facility":"Research Site","city":"Parma","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Research Site","city":"Rome","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Research Site","city":"Rozzano-Milano","country":"Italy"},{"facility":"Research Site","city":"Sassari","country":"Italy","geoPoint":{"lat":40.72586,"lon":8.55552}},{"facility":"Research Site","city":"Trento","country":"Italy","geoPoint":{"lat":46.06787,"lon":11.12108}},{"facility":"Centro Oncologico de Chihuahua","city":"Chihuahua City","state":"Chihuahua","country":"Mexico","geoPoint":{"lat":28.63528,"lon":-106.08889}},{"facility":"Consultorio del","city":"Morelia","state":"Michoacán","country":"Mexico","geoPoint":{"lat":19.70078,"lon":-101.18443}},{"facility":"Instituto Nacional de Cancerologia (INCAN)","city":"Mexico City","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Research Site","city":"Amsterdam","state":"North Holland","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Research Site","city":"Amsterdam","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Research Site","city":"Eindhoven","country":"Netherlands","geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"Research Site","city":"Hoofdrop","country":"Netherlands"},{"facility":"Research Site","city":"Tilburg","country":"Netherlands","geoPoint":{"lat":51.55551,"lon":5.0913}},{"facility":"Research Site","city":"Zwolle","country":"Netherlands","geoPoint":{"lat":52.5125,"lon":6.09444}},{"facility":"Research Site","city":"Warsaw","state":"Masovian Voivodeship","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Bialystok","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Research Site","city":"Bydgoszcz","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Research Site","city":"Bytom","country":"Poland","geoPoint":{"lat":50.34802,"lon":18.93282}},{"facility":"Research Site","city":"Gdynia","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Research Site","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Genova","city":"Lodz","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Research Site","city":"Olsztyn","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Research Site","city":"Otwock","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Research Site","city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Research Site","city":"Torun","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Genova","city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Wroclaw","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Research Site","city":"Zabrze","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Genova","city":"Coimbra","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Genova","city":"Lisbon","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Genova","city":"Porto","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Genova","city":"Santa Maria de Feira","country":"Portugal"},{"facility":"Research Site","city":"Bucharest","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Research Site","city":"Cluj-Napoca","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Research Site","city":"Iași","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Research Site","city":"Sibiu","country":"Romania","geoPoint":{"lat":45.8,"lon":24.15}},{"facility":"Research Site","city":"Suceava","country":"Romania","geoPoint":{"lat":47.63333,"lon":26.25}},{"facility":"Research Site","city":"Timișoara","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Reseaerch Site","city":"Kazan'","state":"Tatarstan Republic","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Research Site","city":"Yaroslavl","state":"Yaroslavlr","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"Research Site","city":"Barnaul","country":"Russia","geoPoint":{"lat":53.36199,"lon":83.72786}},{"facility":"Genova","city":"Chelaybinsk","country":"Russia"},{"facility":"Research Site","city":"Ivanovo","country":"Russia","geoPoint":{"lat":56.99988,"lon":40.97257}},{"facility":"Research Site","city":"Kazan'","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Research Site","city":"Moscow","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Obninsk","country":"Russia","geoPoint":{"lat":55.10993,"lon":36.61238}},{"facility":"Research Site","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Tomsk","country":"Russia","geoPoint":{"lat":56.50049,"lon":84.98216}},{"facility":"Research Site","city":"Voronezh","country":"Russia","geoPoint":{"lat":51.66833,"lon":39.19204}},{"facility":"Research Site","city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Bratislava","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Research Site","city":"Košice","country":"Slovakia","geoPoint":{"lat":48.71441,"lon":21.25802}},{"facility":"Research Site","city":"Nitra","country":"Slovakia","geoPoint":{"lat":48.30763,"lon":18.08453}},{"facility":"Research Site","city":"Goyang-si","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Research Site","city":"Seoul","state":"Gyeonggi-do","country":"South Korea"},{"facility":"Research Site","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Mataró","state":"Barcelona","country":"Spain","geoPoint":{"lat":41.54211,"lon":2.4445}},{"facility":"Research Site","city":"Barakaldo","state":"Bilbao","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Research Site","city":"Donostia / San Sebastian","state":"Guipuzcoa","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Research Site","city":"Jaén","state":"Jaen","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Research Site","city":"A Coruña","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Research Site","city":"Alicante","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Research Site","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Burgos","country":"Spain","geoPoint":{"lat":42.34106,"lon":-3.70184}},{"facility":"Research Site","city":"Girona","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Research Site","city":"Lugo","country":"Spain","geoPoint":{"lat":43.00992,"lon":-7.55602}},{"facility":"Research Site","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Málaga","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Gävle","country":"Sweden","geoPoint":{"lat":60.67452,"lon":17.14174}},{"facility":"Research Site","city":"Gothenburg","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Research Site","city":"Lund","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Research Site","city":"Stockholm","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Research Site","city":"Umeå","country":"Sweden","geoPoint":{"lat":63.82842,"lon":20.25972}},{"facility":"Research Site","city":"Uppsala","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"Research Site","city":"Basel","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Research Site","city":"Geneva","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Research Site","city":"Winterthur","country":"Switzerland","geoPoint":{"lat":47.50564,"lon":8.72413}},{"facility":"Research Site","city":"Kaohsiung City","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Research Site","city":"Taichung","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Research Site","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taoyuan District","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}},{"facility":"Research Site","city":"Cornwall","country":"United Kingdom"},{"facility":"Research Site","city":"Edinburgh","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Research Site","city":"Glasgow","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}},{"facility":"Research Site","city":"Guildford","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}},{"facility":"Research Site","city":"Inverness","country":"United Kingdom","geoPoint":{"lat":57.47908,"lon":-4.22398}},{"facility":"Research Site","city":"Leeds","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}},{"facility":"Research Site","city":"Leicester","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Research Site","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"Manchester","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Research Site","city":"Metropolitan Borough of Wirral","country":"United Kingdom","geoPoint":{"lat":53.37616,"lon":-3.10501}},{"facility":"Research Site","city":"Southampton","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}},{"facility":"Research Site","city":"Surrey","country":"United Kingdom"},{"facility":"Research Site","city":"Torquay","country":"United Kingdom","geoPoint":{"lat":50.46198,"lon":-3.52522}}]},"referencesModule":{"references":[{"type":"BACKGROUND","citation":"Butts C, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Helwig C, Falk MH, Shepherd FA. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. American Society of Clinical Oncology - 49th Annual Meeting. 2013; Abstr No. 7500."},{"type":"BACKGROUND","citation":"Shepherd FA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Helwig C, Schroeder A, Butts C. Updated analysis and secondary endpoints with L-BLP25 in unresectable stage III non-small cell lung cancer in the phase III START study. European Society for Medical Oncology 38th Congress - ECCO 17, ESMO 38, ESTRO 32. 2013. Abstr No. 3419."},{"type":"BACKGROUND","citation":"Mitchell P, Butts C, Socinski M, Thatcher N, Wichardt-Johansson G, Ellis P, Gladkov O, Pereira J, Eberhardt W, Horwood K, Szczesna A, Helwig C, Schröder A, Shepherd F. Tecemotide (L-BLP25) in unresectable stage III non-small cell lung cancer in the phase III START study: Further endpoint and exploratory biomarker results. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2779."},{"type":"BACKGROUND","citation":"Thatcher N, Shepherd FA, Mitchell P, Socinski MA, Paredes A, Lambrechts M, Thomas M, Kollmeier J, Zemanová M, Sadjadian P, Peylan-Ramu N, Helwig C, Schröder A, Butts C. Geographic differences in the combined-modality treatment of stage III unresectable non-small cell lung cancer: Results from a global phase III trial of tecemotide (L-BLP25). World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2712."},{"type":"BACKGROUND","citation":"Socinski M, Butts C, Mitchell P, Thatcher N, Scagliotti G, Robinet G, Martin C, Zukin M, Ragulin Y, Bonomi P, Yang CH, Regnault A, Helwig C, de Nigris E, Shepherd F. Exploration of patient health status as measured by the generic preference-based questionnaire EQ-5D alongside the START trial of tecemotide in non-small cell lung cancer. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2744."},{"pmid":"24331154","type":"RESULT","citation":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9."},{"pmid":"24976972","type":"RESULT","citation":"DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15. No abstract available."},{"pmid":"34870327","type":"DERIVED","citation":"Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W, Suo C, Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3."},{"pmid":"25722382","type":"DERIVED","citation":"Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martin C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 1908 participants were screened for eligibility and 1513 participants were enrolled and randomized.","recruitmentDetails":"First/last participant (informed consent): 25 January 2007/31 October 2011. Data cut-off for primary endpoint analysis: 08 August 2012. Participants randomized at 264 centers in 33 countries worldwide.","groups":[{"id":"FG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"FG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1006"},{"groupId":"FG001","numSubjects":"507"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"623"},{"groupId":"FG001","numSubjects":"332"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"175"}]}],"dropWithdraws":[{"type":"Ongoing at data cut-off","reasons":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"175"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"ITT population included all the subject who were randomized.","groups":[{"id":"BG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"BG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1006"},{"groupId":"BG001","value":"507"},{"groupId":"BG002","value":"1513"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.7","spread":"9.1"},{"groupId":"BG001","value":"60.9","spread":"9.0"},{"groupId":"BG002","value":"60.8","spread":"9.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"477"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"691"},{"groupId":"BG001","value":"345"},{"groupId":"BG002","value":"1036"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival time was defined as the time from randomization to death. Participants without events were censored at the last date they were known to be alive or the clinical cut-off date, whatever was earlier.","populationDescription":"Primary analysis set (modified intention-to-treat \\[ITT\\] population) was based on the ITT population but prospectively excluded all participants (274 participants) that were randomized during the 6 months (22 Sep 2009 to 22 Mar 2010) prior to the effective date of clinical hold.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 66 months","groups":[{"id":"OG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"OG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"829"},{"groupId":"OG001","value":"410"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","lowerLimit":"22.5","upperLimit":"29.2"},{"groupId":"OG001","value":"22.3","lowerLimit":"19.6","upperLimit":"25.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1566","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.893","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.763","ciUpperLimit":"1.044"}]},{"type":"SECONDARY","title":"Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)","description":"Time to symptom progression (TTSP) was measured by LCSS. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where higher score indicates worst outcome). Worsening was defined as a 10% increase in the scale breadth from the baseline score. TTSP is defined as the time from randomization to worsening in ASBI. Participants without event are censored at the date of the last LCSS assessment.","populationDescription":"Primary analysis set (modified ITT population) was based on the ITT population but prospectively excluded all participants (274 participants) that were randomized during the 6 months (22 Sep 2009 to 22 Mar 2010) prior to the effective date of clinical hold. \"N\" signifies the number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 66 months","groups":[{"id":"OG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"OG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"829"},{"groupId":"OG001","value":"409"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","lowerLimit":"12.9","upperLimit":"15.7"},{"groupId":"OG001","value":"11.4","lowerLimit":"9.3","upperLimit":"13.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0226","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.845","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.732","ciUpperLimit":"0.977"}]},{"type":"SECONDARY","title":"Time To Progression (TTP)","description":"Time from randomization to disease progression. Disease progression was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 \\[RECIST v1.0\\]) as at least a 20% increase in the sum of the longest diameter of target lesions from nadir, or the appearance of one or more new lesions.","populationDescription":"Primary analysis set (modified ITT population) was based on the ITT population but prospectively excluded all participants (274 participants) that were randomized during the 6 months (22 Sep 2009 to 22 Mar 2010) prior to the effective date of clinical hold.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 66 months","groups":[{"id":"OG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"OG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"829"},{"groupId":"OG001","value":"410"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"9.1","upperLimit":"11.5"},{"groupId":"OG001","value":"8.4","lowerLimit":"7.2","upperLimit":"10.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0528","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.868","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.752","ciUpperLimit":"1.002"}]},{"type":"SECONDARY","title":"One-, Two- and Three-year Survival Rate","description":"The percentages of participants who were alive at 1, 2, and 3 years were calculated as a cumulative percentage by Kaplan-Meier survival analysis approach.","populationDescription":"Primary analysis set (modified ITT population) was based on the ITT population but prospectively excluded all participants (274 participants) that were randomized during the 6 months (22 Sep 2009 to 22 Mar 2010) prior to the effective date of clinical hold.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Years 1, 2, and 3","groups":[{"id":"OG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"OG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"829"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Year 1","categories":[{"measurements":[{"groupId":"OG000","value":"77.0"},{"groupId":"OG001","value":"74.7"}]}]},{"title":"Year 2","categories":[{"measurements":[{"groupId":"OG000","value":"50.8"},{"groupId":"OG001","value":"45.9"}]}]},{"title":"Year 3","categories":[{"measurements":[{"groupId":"OG000","value":"40.2"},{"groupId":"OG001","value":"37.0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions","description":"Treatment -emergent adverse events were defined as those with onset or worsening occurring at or after the first dosing day of study medication and up to 42 days after the last administration of any study drug or the clinical cut-off date. Injection site reactions were reported as assessed by the Investigator.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of trial treatment (cyclophosphamide, tecemotide, saline, or placebo). Participants were reported based on the actual treatment received (as-treated).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From first dose up to 42 days after the last dose of the trial treatment","groups":[{"id":"OG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented."},{"id":"OG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1024"},{"groupId":"OG001","value":"477"}]}],"classes":[{"title":"Treatment Emergent Adverse events","categories":[{"measurements":[{"groupId":"OG000","value":"938"},{"groupId":"OG001","value":"432"}]}]},{"title":"Injection site reaction","categories":[{"measurements":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"56"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 66 months","description":"Safety analysis set included all participants who received at least 1 dose of trial treatment (cyclophosphamide, tecemotide, saline, or placebo). Participants were reported based on the actual treatment received (as-treated).","eventGroups":[{"id":"EG000","title":"Tecemotide (L-BLP25) + Cyclophosphamide","description":"A single intravenous infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before first tecemotide (L-BLP25) vaccination. After receiving cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression was documented.","seriousNumAffected":303,"seriousNumAtRisk":1024,"otherNumAffected":918,"otherNumAtRisk":1024},{"id":"EG001","title":"Saline + Placebo","description":"A single intravenous infusion of 0.9 percent (%) saline solution in the same calculated dose as cyclophosphamide was given 3 days before first placebo vaccination. After receiving saline, participants received 8 consecutive weekly subcutaneous vaccinations with placebo at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at Week 13, until disease progression was documented.","seriousNumAffected":151,"seriousNumAtRisk":477,"otherNumAffected":417,"otherNumAtRisk":477}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Haemolytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Hypocoagulable state","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":4,"numAtRisk":477}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Coronary artery occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Sick sinus syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Retinal vascular thrombosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Aphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Hernial eventration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Intestinal infarction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Oesophageal dilatation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pancreatitis chronic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":1024},{"groupId":"EG001","numAffected":11,"numAtRisk":477}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":3,"numAtRisk":477}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Spinal pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hepatitis alcoholic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Helicobacter gastritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Herpes zoster disseminated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":1024},{"groupId":"EG001","numAffected":4,"numAtRisk":477}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Mastitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":1024},{"groupId":"EG001","numAffected":14,"numAtRisk":477}]},{"term":"Pneumonia primary atypical","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Salmonella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Meniscus lesion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Radiation associated pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Radiation myelopathy","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":1024},{"groupId":"EG001","numAffected":5,"numAtRisk":477}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Traumatic lung injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Vascular pseudoaneurysm","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Wound evisceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Muscle atrophy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Bile duct cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":1024},{"groupId":"EG001","numAffected":9,"numAtRisk":477}]},{"term":"Metastases to kidney","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Metastases to large intestine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to lymph nodes","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to pancreas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to salivary gland","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Metastases to small intestine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Oncologic complication","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Paraneoplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Prostatic adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Thyroid neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Tonsil cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Tumour invasion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Carotid artery dissection","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Carotid artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Cataplexy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Guillain-Barre syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Monoparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Nerve root compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Spermatocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Bronchial haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Bronchostenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":7,"numAtRisk":477}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":1024},{"groupId":"EG001","numAffected":13,"numAtRisk":477}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":1024},{"groupId":"EG001","numAffected":5,"numAtRisk":477}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Laryngeal cyst","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Oesophagobronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":1024},{"groupId":"EG001","numAffected":12,"numAtRisk":477}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":1024},{"groupId":"EG001","numAffected":2,"numAtRisk":477}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":1024},{"groupId":"EG001","numAffected":4,"numAtRisk":477}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":4,"numAtRisk":477}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Pericardial drainage","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Femoral arterial stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Peripheral artery aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Temporal arteritis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1024},{"groupId":"EG001","numAffected":1,"numAtRisk":477}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1024},{"groupId":"EG001","numAffected":0,"numAtRisk":477}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":1024},{"groupId":"EG001","numAffected":26,"numAtRisk":477}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":1024},{"groupId":"EG001","numAffected":46,"numAtRisk":477}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":140,"numAtRisk":1024},{"groupId":"EG001","numAffected":39,"numAtRisk":477}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":1024},{"groupId":"EG001","numAffected":26,"numAtRisk":477}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":71,"numAtRisk":1024},{"groupId":"EG001","numAffected":29,"numAtRisk":477}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":130,"numAtRisk":1024},{"groupId":"EG001","numAffected":43,"numAtRisk":477}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":195,"numAtRisk":1024},{"groupId":"EG001","numAffected":102,"numAtRisk":477}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":1024},{"groupId":"EG001","numAffected":27,"numAtRisk":477}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":1024},{"groupId":"EG001","numAffected":24,"numAtRisk":477}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":80,"numAtRisk":1024},{"groupId":"EG001","numAffected":41,"numAtRisk":477}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":83,"numAtRisk":1024},{"groupId":"EG001","numAffected":38,"numAtRisk":477}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":128,"numAtRisk":1024},{"groupId":"EG001","numAffected":44,"numAtRisk":477}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":96,"numAtRisk":1024},{"groupId":"EG001","numAffected":37,"numAtRisk":477}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":77,"numAtRisk":1024},{"groupId":"EG001","numAffected":30,"numAtRisk":477}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":109,"numAtRisk":1024},{"groupId":"EG001","numAffected":44,"numAtRisk":477}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":108,"numAtRisk":1024},{"groupId":"EG001","numAffected":33,"numAtRisk":477}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":146,"numAtRisk":1024},{"groupId":"EG001","numAffected":52,"numAtRisk":477}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":1024},{"groupId":"EG001","numAffected":22,"numAtRisk":477}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":92,"numAtRisk":1024},{"groupId":"EG001","numAffected":33,"numAtRisk":477}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":73,"numAtRisk":1024},{"groupId":"EG001","numAffected":18,"numAtRisk":477}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":1024},{"groupId":"EG001","numAffected":29,"numAtRisk":477}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":87,"numAtRisk":1024},{"groupId":"EG001","numAffected":37,"numAtRisk":477}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":123,"numAtRisk":1024},{"groupId":"EG001","numAffected":54,"numAtRisk":477}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":1024},{"groupId":"EG001","numAffected":25,"numAtRisk":477}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":336,"numAtRisk":1024},{"groupId":"EG001","numAffected":133,"numAtRisk":477}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":225,"numAtRisk":1024},{"groupId":"EG001","numAffected":103,"numAtRisk":477}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":1024},{"groupId":"EG001","numAffected":32,"numAtRisk":477}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":1024},{"groupId":"EG001","numAffected":27,"numAtRisk":477}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"After conclusion of the study, an integrated clinical and statistical study report shall be written by the Sponsor in consultation with the Coordinating Investigator based on the protocol. The first publication will be a full publication of all data from all sites. The Sponsor is entitled to delay publication in order to obtain patent protection. The ICMJE criteria for authorship will be followed. A separate publication plan will be set up to describe further publications."},"pointOfContact":{"title":"Merck KGaA Communication Center","organization":"Merck Serono, a division of Merck KGaA","email":"service@merckgroup.com","phone":"+49-6151-72-5200"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Ukraine"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C518273","term":"L-BLP25"},{"id":"D012847","term":"Single Person"},{"id":"D003520","term":"Cyclophosphamide"}],"ancestors":[{"id":"D017533","term":"Marital Status"},{"id":"D005191","term":"Family Characteristics"},{"id":"D003710","term":"Demography"},{"id":"D011154","term":"Population Characteristics"},{"id":"D012959","term":"Socioeconomic Factors"},{"id":"D010752","term":"Phosphoramide Mustards"},{"id":"D009588","term":"Nitrogen Mustard Compounds"},{"id":"D009150","term":"Mustard Compounds"},{"id":"D006846","term":"Hydrocarbons, Halogenated"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D063088","term":"Phosphoramides"},{"id":"D009943","term":"Organophosphorus Compounds"}]}},"hasResults":true}